Humulin Regular (Dialytí) (Insulin Human (Rdna))

Humulin Regular (Dialytí) is indicated for several clinical situations where rapid reduction of blood glucose is required.

• Type 1 diabetes mellitus to control basal‑bolus insulin regimens.
• Type 2 diabetes mellitus as part of a comprehensive treatment plan when oral agents are insufficient.
• Hospital‑managed hyperglycemia, such as peri‑operative or critical‑care settings.
• Gestational diabetes when rapid‑acting insulin is preferred (use under medical supervision).
• Correction of acute hyperglycemic episodes, including diabetic ketoacidosis, when administered intravenously.

• Humulin Regular (Dialytí) delivers recombinant human insulin that binds to insulin receptors on muscle, adipose, and hepatic cells. Receptor activation triggers autophosphorylation of the β‑subunit, initiating the PI3‑K/Akt signaling cascade, which promotes translocation of GLUT‑4 transporters to the cell membrane, increasing glucose uptake. Concurrently, insulin suppresses hepatic gluconeogenesis and glycogenolysis, thereby lowering circulating glucose concentrations. The rapid onset of action reflects its short molecular modifications, allowing peak effect within 2–4 hours after subcutaneous injection.

Adverse reactions to Humulin Regular (Dialytí) are categorized by frequency and clinical significance.

Common

• Hypoglycemia, presenting as sweating, tremor, or confusion.
• Injection site reactions such as redness, swelling, or itching.
• Lipodystrophy, including localized lipoatrophy or lipohypertrophy at repeated injection sites.
• Weight gain associated with improved glycemic control.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions ranging from urticaria to anaphylaxis.
• Edema or heart failure exacerbation in susceptible patients.
• Hypokalemia due to rapid intracellular shift of potassium.

Before initiating therapy with Humulin Regular (Dialytí), clinicians should consider several precautionary factors to ensure safe use.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Review patient’s history of hypoglycemia unawareness or recurrent episodes.
• Adjust doses when patients are fasting, ill, or undergoing surgery.
• Monitor for signs of fluid retention or worsening heart failure.
• Counsel pregnant or breastfeeding women that safety data are limited and require medical supervision.
• Evaluate for potential lipodystrophy with repeated injections at the same site.
• Consider age‑related dosing adjustments in pediatric and geriatric populations.

Humulin Regular (Dialytí) can interact with other medications, affecting glucose control or insulin activity.

Avoid

• Co‑administration of other rapid‑acting insulins without dose reduction.
• Beta‑blockers that may conceal hypoglycemia signs.
• High‑dose systemic corticosteroids that raise glucose levels.

Use with caution

• Sulfonylureas or meglitinides, increasing hypoglycemia risk.
• Thiazide diuretics, which can reduce insulin sensitivity.
• Alcohol intake, especially without food, which may cause delayed hypoglycemia.